美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Lakewood-Amedex Biotherapeutics (Direct Listing)

0.3861

-0.2161-35.89%

盤後：0.39200.0059+1.53%19:49 EDT

成交量：183.08萬

成交額：77.89萬

市值：552.91萬

市盈率：-1.31

高：0.5895

開：0.5630

低：0.3660

收：0.6022

52周最高：9.82

52周最低：0.3660

股本：1,432.04萬

流通股本：470.00萬

量比：5.03

換手率：38.95%

股息：- -

股息率：- -

每股收益(TTM):-0.2950

每股收益(LYR):-0.8399

淨資產收益率：--

總資產收益率：-303.80%

市淨率：-2.81

市盈率(LYR):-0.46

資料載入中...

總覽公司新聞公告

Lakewood-Amedex Biotherapeutics：關鍵製劑、遞送與生產步驟完成，為計劃中的二期臨床試驗做準備

Lakewood-Amedex Biotherapeutics 宣佈其領先候選藥物 Nu-3 在治療感染性糖尿病足潰瘍方面取得積極數據

Lakewood-Amedex Biotherapeutics 宣佈與Peri達成協議，後者將擔任Nu-3二期臨床試驗的合同研究組織

Lakewood-Amedex Biotherapeutics公司Nu-3保持對環丙沙星耐藥菌的活性

Lakewood-Amedex Biotherapeutics公布針對感染性糖尿病足潰瘍的主要候選藥物抗微生物耐藥性積極數據

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/LABT/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":0.3861,"timestamp":1781812800000,"preClose":0.6022,"halted":3,"volume":1830790,"hourTrading":{"tag":"盘后","latestPrice":0.392,"preClose":0.3861,"latestTime":"19:49 EDT","volume":348281,"amount":143405.323819,"timestamp":1781826588480,"change":0.0059,"changeRate":0.015281,"amplitude":0.240611},"delay":0,"changeRate":-0.3588508801062769,"floatShares":4700000,"shares":14320400,"eps":-0.295,"marketStatus":"停牌","change":-0.2161,"latestTime":"06-18 16:00:00 EDT","open":0.563,"high":0.589499,"low":0.366,"amount":778912.2235297001,"amplitude":0.371137,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.295,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":0.6022,"preHourTrading":{"tag":"盘前","latestPrice":0.572,"preClose":0.614,"latestTime":"09:29 EDT","volume":21539,"amount":12121.554723599998,"timestamp":1781789349300,"change":-0.042,"changeRate":-0.068404,"amplitude":0.031922},"postHourTrading":{"tag":"盘后","latestPrice":0.392,"preClose":0.3861,"latestTime":"19:49 EDT","volume":348281,"amount":143405.323819,"timestamp":1781826588480,"change":0.0059,"changeRate":0.015281,"amplitude":0.240611},"volumeRatio":5.025763079330368},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","floatShares":4700000,"roa":"-303.80%","roe":"--","lyrEps":-0.839872,"volumeRatio":5.025763079330368,"shares":14320400,"dividePrice":0,"high":0.589499,"amplitude":0.371137,"preClose":0.6022,"low":0.366,"week52Low":0.366,"pbRate":"-2.81","week52High":9.82,"institutionHeld":0,"latestPrice":0.3861,"eps":-0.295,"divideRate":0,"volume":1830790,"delay":0,"ttmEps":-0.295,"open":0.563,"prevYearClose":8,"prevWeekClose":0.7674,"prevMonthClose":0.675,"prevQuarterClose":8,"fiveDayClose":0.7228,"twentyDayClose":0.753},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-06-22","symbol":"LABT","defaultRemindTime":1782135000000,"type":"split","dateTimestamp":1782100800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LABT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LABT","date":"2026-06-18","current":-1.308814,"percent":1,"low":-12.282138,"twenty":-11.42611,"median":-2.776507,"eighty":-2.512255,"high":-2.241304,"avg":-5.17349,"sd":3.910892,"marketCap":8623724},"quantilePoints":[{"date":"2026-05-08","current":-12.282138,"twenty":-12.192813,"median":-11.891342,"eighty":-11.604759,"marketCap":47257207},{"date":"2026-05-15","current":-7.294845,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"marketCap":28067917},{"date":"2026-05-22","current":-2.865088,"twenty":-11.850402,"median":-11.258627,"eighty":-3.412052,"marketCap":11023817},{"date":"2026-05-29","current":-2.716586,"twenty":-11.716415,"median":-6.438817,"eighty":-2.758568,"marketCap":10452435},{"date":"2026-06-05","current":-2.512255,"twenty":-11.604759,"median":-3.225364,"eighty":-2.559299,"marketCap":9666247},{"date":"2026-06-12","current":-2.69016,"twenty":-11.537766,"median":-2.813168,"eighty":-2.512255,"marketCap":10350760},{"date":"2026-06-18","current":-2.241304,"twenty":-11.42611,"median":-2.776507,"eighty":-2.512255,"marketCap":8623724}],"updateTime":1781945594050},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABT\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1187732926","title":"Lakewood-Amedex Biotherapeutics：關鍵製劑、遞送與生產步驟完成，為計劃中的二期臨床試驗做準備","url":"https://stock-news.laohu8.com/highlight/detail?id=1187732926","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187732926?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 20:06","pubTimestamp":1779105973,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 宣布，已成功完成关键制剂、药物递送及生产工艺步骤，为其计划开展的二期临床试验做好了充分准备。这些进展标志着公司在推进其候选疗法方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165537088","title":"Lakewood-Amedex Biotherapeutics 宣佈其領先候選藥物 Nu-3 在治療感染性糖尿病足潰瘍方面取得積極數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1165537088","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165537088?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 20:03","pubTimestamp":1779105797,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 公布了其领先候选药物 Nu-3 在治疗感染性糖尿病足溃疡方面取得积极数据，这标志着该药物研发进程的又一重要进展。这些数据为 Nu-3 的进一步临床开发提供了有力支持，有望为这一难治性感染领域带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184734412","title":"Lakewood-Amedex Biotherapeutics 宣佈與Peri達成協議，後者將擔任Nu-3二期臨床試驗的合同研究組織","url":"https://stock-news.laohu8.com/highlight/detail?id=1184734412","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184734412?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 20:03","pubTimestamp":1778587406,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已正式宣布与Peri公司达成一项合作协议。根据协议条款，Peri公司将作为合同研究组织，负责其候选药物Nu-3的二期临床试验工作。此举标志着该药物研发进程迈入了新的关键阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159948293","title":"Lakewood-Amedex Biotherapeutics公司Nu-3保持對環丙沙星耐藥菌的活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1159948293","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159948293?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 20:04","pubTimestamp":1777637062,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics公司宣布，其创新抗菌药物Nu-3在最新实验研究中展现出持续对抗环丙沙星耐药菌的显著活性。这一突破性发现为应对日益严峻的抗生素耐药性问题提供了新的解决方案。\n研究数据表明，Nu-3不仅能有效抑制对环丙沙星产生耐药性的菌株，其抗菌机制还展现出与传统抗生素不同的作用路径。这种独特的分子结构设计使其能够规避细菌常见的耐药机制，为开发新一代抗菌疗法开辟了前景。\n该成果对公共卫生领域具有重要意义，特别是在治疗多重耐药菌感染方面显示出潜在临床应用价值。公司将继续推进相关研究，进一步验证Nu-3在更广泛病原体中的抗菌效能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161086272","title":"Lakewood-Amedex Biotherapeutics公布針對感染性糖尿病足潰瘍的主要候選藥物抗微生物耐藥性積極數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1161086272","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161086272?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 20:04","pubTimestamp":1777637056,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics公司近日披露了其针对感染性糖尿病足溃疡的主要候选药物在抗微生物耐药性方面取得的积极研究数据。这项进展标志着该公司在开发新型抗菌疗法领域迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}